October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg’s Efficacy for Essential Thrombocythemia
Sep 5, 2025, 12:18

Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg’s Efficacy for Essential Thrombocythemia

MPN Hub shared on X:

”CONGRESS | SOHO 2025 | POSTER
Lucia Masarova, MD Anderson Cancer Center

Presents results from the phase III SURPASS-ET trial of ropeginterferon alfa-2b (n=91) vs anagrelide (n=83) in patients with HR Essential Thrombocythemia who are resistant or intolerant to hydroxyurea.

Ropeg showed superior efficacy over anagrelide (RR, 42.9% vs 6.0%, P=0.0001) and demonstrated a favorable safety profile.”

Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg's Efficacy for Essential Thrombocythemia

All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.